Page last updated: 2024-09-04

dx 8951 and Acute Myelogenous Leukemia

dx 8951 has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beran, M; Giles, FJ; Jeha, S; Kantarjian, H; Smith, TL; Vey, N	1

Other Studies

1 other study(ies) available for dx 8951 and Acute Myelogenous Leukemia

Article	Year
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Survival Analysis; Time Factors; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured	2000

Article

Year

The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:2

Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Survival Analysis; Time Factors; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured

2000